Tissue-specific regulation of ACE/ACE2 and AT 1 /AT 2 receptor gene expression by oestrogen in apolipoprotein E/oestrogen receptor-α knock-out mice: Oestrogen regulation of ACE/ACE2 and AT1/AT2 by Brosnihan, K. Bridget et al.
Tissue Specific Regulation of ACE/ACE2 and AT1/AT2 Receptor
Gene Expression By Estrogen in ApoE/ERα Knock-Out Mice
K. Bridget Brosnihan1, Jeffrey B. Hodgin2, Oliver Smithies2, Nobuyo Maeda2, and Patricia
Gallagher1
1The Hypertension and Vascular Research Center, Wake Forest University Health Sciences, Winston-Salem,
NC 27157-1932, USA
2Department of Pathology and Laboratory Medicine, University of North Carolina, Chapel Hill, NC
Summary
ACE and ACE2 and the AT1 and AT2 receptors are pivotal points of regulation in the renin-
angiotensin system. ACE and ACE2 are key enzymes in the formation and degradation of Ang II
and Ang-(1-7). Ang II acts at either the AT1 or the AT2 receptor to mediate opposing actions of
vasoconstriction/vasodilation. While it is known that estrogen (E2) acts to down-regulate ACE and
the AT1 receptors, its regulation of ACE2 and the AT2 receptor and the involvement of a specific
estrogen receptor subtype are unknown. To investigate the role of estrogen receptor-α (ERα) in
estrogen’s regulation of ACE/ACE2 and AT1/AT2 mRNAs in lung and kidney, ovariectomized
female mice lacking apolipoprotein E (ee) with the ERα (AAee) or without the ERα (ααee) were
treated with 17-β estradiol (6 µg/day) or placebo for 3 months. ACE,ACE2 and AT1/AT2 receptor
mRNAs were measured using reverse transcriptase, real-time polymerase chain reaction (RT/RT-
PCR). In the kidney, 17-β estradiol showed 1.7 fold down-regulation of ACE mRNA in AAee mice,
with 2.1-fold up-regulation of ACE mRNA in ααee mice. 17-β estradiol showed 1.5 and 1.8 fold
down-regulation of ACE2 and AT1 receptor mRNA in AAee mice; this regulation was lost in ααee
mice. 17-β estradiol showed marked (81-fold) up-regulation of the AT2 receptor mRNA in AAee
mice. In the lung 17-β estradiol treatment had no effect on AT1 receptor mRNA in AAee mice, but
resulted in a 1.5-fold decreased regulation of AT1 mRNA in ααee. There was no significant
interaction of estrogen with ER in the lung for ACE, ACE2, and AT2 receptor genes. These studies
reveal tissue specific regulation by 17-β estradiol of ACE/ACE2 and AT1/AT2 receptor genes with
the ERα receptor primarily responsible for the regulation of kidney ACE2 , AT1 receptor, and AT2
receptor genes.
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Introduction
In previous studies the inhibitory effects of estrogen (E2) on atherosclerosis were well-
documented in numerous animal models (Clarkson et al., 1996;Clarkson et al., 1994). A mouse
model of atherosclerosis that results in severe atherosclerotic lesions is the apolipoprotein E-
deficient (ApoE−/−) mouse. Long term estrogen treatment was highly effective in inhibiting
lesion progression (Hodgin et al., 2001). The long term effects of E2 are generally ascribed to
transcriptional modulation of target genes through estrogen receptors (ERs). Two estrogen
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receptors, ERα and ERβ, encoded by two separate genes were characterized, are distinct
structurally and functionally, and have tissue specific expression patterns. Both receptors are
expressed in a variety of cardiovascular cells types. Using the ApoE−/− that lack the ERα,
Hodgin et al (Hodgin et al., 2001) showed that 17-β estradiol treatment of ovariectomized
ApoE−/− mice with the ERα attenuated the artherosclerosis, but that ApoE−/− mice without
the ERα caused minimal reduction in artherosclerosis with E2 treatement. These studies
demonstrated that ERα is a major mediator of the atheroprotective effects of E2. This mouse
model was instrumental in uncovering the receptor subtype that mediates E2 effects on
atherosclerosis.
Many components of the renin-angiotensin system (RAS) are regulated by E2. ACE mRNA
and activity, as well as the AT1 receptor, are down-regulated by E2 (Brosnihan et al.,
1999;Gallagher et al., 1999;Brosnihan et al., 2000;Wu et al., 2003;Krishnamurthi et al.,
1999;Nickenig et al., 1998). The role of E2 in the regulation of ACE2, a recently described
homologue of ACE that shows high catalytic activity in the degradation of Ang II (Burrell et
al., 2004;Shaltout et al., 2007), has not been determined, but we showed that ACE2 mRNA
and activity are increased in the kidney and uterus of pregnant animals (Joyner et al.,
2007;Neves et al., 2007) making estrogen a likely modulator for ACE2 regulation, although
other hormones could be involved. There are few studies describing the effect of E2 on AT2
receptor regulation. The objective of these studies was to study the role of E2 in the regulation




Frozen mouse tissues were obtained from Dr. Jeffrey B. Hodgin and the results from his study
are described in a previous publication (Hodgin et al., 2001). The protocols for the mouse
experiments were approved by the Institutional Animal Care and Use Committee of the
University of North Carolina at Chapel Hill, NC. The experimental animals used for
investigating the role of the ERα were female ApoE−/− (designated ee) with or without ERα
[designated AA or αα] on a C57Bl6/J genetic background. The four groups were 1) animals
with the ERα and ee (AAee) and no 17-β estradiol treatment; 2) AAee animals plus 17-β
estradiol treatment; 3) animals without the ERα (ααee) without 17-β estradiol treatment; and
4) ααee animals plus 17-β estradiol treatment. At 30 days of age, female mice were weighed,
ovariectomized and randomly implanted subcutaneously with either pellets designed to release
17-β estradiol at 6 µg/day (0.36 mg/pellet with 60-day release) for 60 days or a placebo control
(Innovative Research of America, Sarasota, FL). Pellets (additional pellets with 60-day release)
were replaced 60 days after surgery and the mice were sacrificed 30 days later at 4 months of
age. Mice were maintained in a specific pathogen free condition on standard mouse chow
(Prolab Isopro RMH3000; PMI Nutrition International, Brentwood, MI).
RNA Isolation and Reverse Transcriptase/Real-time Polymerase Chain Reaction (RT-RTPCR)
The concentration and integrity of RNA isolated from mouse kidney or lung tissue using the
TRIZOL reagent was assessed with an Agilent 2100 Bioanalyzer. Total RNA was reverse
transcribed and the resultant cDNA was amplified with an ABI 7000 Sequence Detection
System. The primer/probe sets for AT1 receptor, AT2 receptor, and ACE were purchased from
Applied Biosystems (Foster City, CA); the ACE2 primer/probe set consisted of forward primer
5’-CCCAGAGAACAGTGGACCAAAA-3’, reverse primer 5’-
GCTCCACCACACCAACGAT-3’, and probe 5’-FAM-CTCCCGCTTCATCTCC-3’. The
mixtures were heated at 50°C for 2 min, at 95°C for 10 min followed by 40 cycles at 95°C for
15 sec and 60°C for 1 min. All reactions were performed in triplicate and 18S ribosomal RNA
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served as an internal control. Undegraded total RNA samples were used to evaluate the integrity
of 18S and 28S rRNA, which show distinct 18s and 28S rRNA subunit peaks with a ratio of
1.85. The results were quantified as Ct values, where Ct is defined as the threshold cycle of
PCR at which amplified product is first detected, and expressed as the ratio of target/control
(Relative Gene Expression).
Radioimmunoassay of 17-β Estradiol
17-β estradiol was assayed on serum using a radioimmunoassay kit (Diagnostic Systems
Laboratories, Webster, TX).
Statistical analysis
Comparisons between the groups were performed using a 2-way ANOVA. Fisher LSD multiple
comparison test was used (Number Cruncher Statistical Systems, Kaysville, Utah). A p value
less than 0.05 was considered statistically significant. All values are presented as mean±SEM.
Results
Serum 17-β estadiol levels of the placebo treated mice were < 20 pg/ml; whereas serum 17-β
estadiol levels of the estrogen treated animals were 72 ± 20 pg/ml in the AAee and 104 ± 17
pg/ml in the ααee groups, as previously reported (Hodgin et al., 2001).
Estrogen effects on kidney ACE/ACE2 and AT1/AT2 mRNAs
Figure 1 shows that chronic estrogen treatment reduced ACE mRNA by 1.7-fold in ApoE−/−
mice possessing the ERα (AAee) agreeing with previously reported findings in ovariectomized
Sprague Dawley rats treated with estradiol (Brosnihan et al., 2000;Gallagher et al., 1999). 17-
β estradiol treatment resulted in a 2.1-fold up-regulation of kidney ACE mRNA in the ApoE
−/−ERα KO mice (ααee). 17-β estradiol treatment down-regulated kidney ACE2 and AT1
receptor mRNAs by 1.5-and 1.8-fold, respectively, in AAee; and this regulation by 17-β
estradiol treatment was lost in ααee mice (Figure 1), suggesting that ERα is the primary
regulator of the ACE2 and the AT1 receptor mRNAs. 17-β estradiol showed marked up-
regulation by 81-fold of the AT2 receptor mRNA in AAee mice, which was markedly reduced
in ααee mice, suggesting that ERα contributes to the up-regulation of the kidney AT2 receptor.
The increase with 17-β estradiol treatment in ααee did not reach statistical significance.
Estrogen effects on lung ACE/ACE2 and AT1/AT2 mRNAs
In the lung 17-β estradiol treatment resulted in a 1.5 fold down-regulation of AT1 mRNA in
lung in the absence of ERα, suggesting that ERβ mediates the 17-β estradiol effect on AT1
mRNA (Figure 2). There was no significant interaction between 17-β estradiol and the ER for
ACE, ACE2 and AT2 receptor mRNAs in lung. However, an effect of estrogen was observed
in ααee mice for ACE and ACE2 mRNA.
Discussion
Estrogen exerts complex regulation over the components of the RAS. The most clear
demonstration of estrogen’s effects on the RAS are the reports that E2 up-regulates
angiotensinogen in the liver (Nasjletti et al., 1969) and down-regulates ACE (Brosnihan et
al., 2000;Gallagher et al., 1999) and AT1 receptor in the kidney, adrenal and vasculature (Wu
et al., 2003;Krishnamurthi et al., 1999;Nickenig et al., 1998). With the development of ER
knock-out mice, it is possible to uncover the role of a specific subtype of the ER that regulates
the expression of the genes of the RAS. In these studies using the ApoEKO mice with and
without the ERα, we demonstrated that the ERα receptor down-regulates ACE2 and the AT1
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receptor mRNA in the kidney, since these effects of 17-β estradiol were absent in the ααee
mice treated with 17-β estradiol. 17-β estradiol also down-regulated ACE mRNA in kidney
tissues, but in the ααee mice the down-regulation was reversed to up-regulation. By inference,
it appears that ERβ may contribute to the up-regulation of kidney ACE mRNA, which becomes
uncovered in the absence of ERα. The most striking effect of 17-β estradiol in this study was
the demonstration that 17-β estradiol resulted in 81-fold up-regulation of the AT2 receptor in
the kidney. Because the increase in AT2 receptor mRNA in the kidney with 17-β estradiol
treatment was lost in the ApoE/ERα KO mice as compared to AAee mouse, a primary role for
ERα is likely. However, because there was a trend for the AT2 receptor mRNA to be influenced
by 17-β estradiol in the ααee mice the contribution of ERβ on its regulation cannot be
eliminated. In the lung only the AT1 receptor mRNA showed a significant interaction of 17-
β estradiol with ER. Because the regulation by estrogen was only uncovered in the ααee mice,
it appears that ERβ may contribute to the down-regulation of the AT1 receptor gene in the lung.
Because these studies were not done in ERβKO mice, the direct participation of the ERβ awaits
studies in the ERβKO mice, but the ααee model allows us to suggest a role of ERβ by inference.
These studies reveal tissue specific regulation by 17-β estradiol of ACE/ACE2 and AT1/AT2
receptor genes with the ERα receptor primarily responsible for the regulation of kidney ACE2,
AT1 receptor, and AT2 receptor genes. The participatory role of ERβ seems likely in regard to
the regulation of kidney ACE mRNA and lung AT1 receptor mRNA.
The down-regulation of ACE by estrogen is well established (Brosnihan et al., 2000;Gallagher
et al., 1999;Seely et al., 2004;Proudler et al., 2003). 17-β estradiol treatment in ovariectomized
rats decreased ACE mRNA and activity in renal cortex and medulla and aorta (Brosnihan et
al., 2000;Gallagher et al., 1999). Post-menopausal women on hormone replacement also show
a decreased serum ACE activity (Seely et al., 2004;Proudler et al., 2003). While no estrogen
response element has been found in the ACE coding sequence, it is thought that an ACE
promoter may be responsive to actions of gene transcription factors independent of the hormone
response element. The ACE promoter does contain a consensus AP1 site that could mediate
the effects of exogenous estrogen (Goraya et al., 1994;Howard et al., 1993). Our studies
demonstrated that kidney ACE mRNA was reduced with 17-β estradiol treatment. In mice
lacking the ERα, estrogen replacement resulted in increased kidney ACE mRNA. This finding
indicates that ERα is not the only receptor subtype involved in the regulation of ACE mRNA.
It is known that ααee mice do not express the wild type gene encoding ERα; however, a small
splice variant of the disrupted ERα gene along with a residual level of ERα binding was
described. Since the binding was detected only in the uterus and not in other tissue, such as
kidney, liver, and brain (Couse et al., 1995), it is unlikely that the ERα splice variant is involved
in kidney ACE mRNA regulation. The most likely candidate to explain the E2 effect in the
absence of ERα is the ERβ. Because ACE mRNA was up-regulated by E2 in mice lacking
ERα, this finding also suggests the involvement of ERβ contributing to the up-regulation of
the ACE gene.
Most of the traditionally observed effects of the RAS are mediated by the AT1 receptor. Like
ACE, the AT1 receptor is down-regulated by 17-β estradiol replacement therapy (Wu et al.,
2003;Krishnamurthi et al., 1999;Nickenig et al., 1998). Studies in humans as well as
experimental animals report this action of E2 at the level of the gene, receptor density, and
protein (Wu et al., 2003;Krishnamurthi et al., 1999;Nickenig et al., 1998). Our studies on the
AT1 receptor demonstrate down-regulation by 17-β estradiol in the kidney, but no effect of 17-
β estradiol on the lung AT1 receptor mRNA in AAee The significant down-regulation of the
lung AT1 receptor that appears in the ααee mice with 17-β estradiol replacement suggests a
role for the ERβ that may be masked by the ERα.
Both the kidney and lung express ACE2 activity, mRNA and protein (Gembardt et al.,
2005;Riviere et al., 2005). The kidney and ileum of the mouse show the highest level as
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compared to all tissues, with the lung showing ACE2 expression to a lesser degree (Gembardt
et al., 2005). Few studies have been conducted to evaluate the regulation of the ACE2 gene.
It is known that there is up-regulation of ACE2 in heart failure (Goulter et al., 2004). Both Ang
II through activation of the AT1 receptor (Gallagher et al., 2006) and aldosterone down-regulate
ACE2 (Keidar et al., 2005). The role of estrogen in its regulation is not so clear. Recently,
Ojeda et al (Ojeda et al., 2007) showed that female offspring of intrauterine growth restricted
(IUGR) mothers displayed a 6-fold increase in ACE2 activity as compared to control females,
which was reduced by ovariectomy in IUGR female offspring, but not control females. The
lack of effect in ovariectomized controls was suggested to reflect a permanent alteration in the
regulation of RAS components in the offsping of IUGR animals. 17-β estradiol treatment was
associated with up-regulation of renal ACE2 in the renal wrap model of hypertension (Ji et
al., 2007). Finally, pregnant animals showed an increase in ACE2 immunocytochemical
expression and activity in renal cortex and medulla (Joyner et al., 2007) in late gestation, the
up-regulation being consistent with the high levels of estrogen that are found in pregnancy.
These findings suggest that estrogen up-regulates ACE2 gene expression, but that the
regulation may differ under pathological conditions. The current studies using 17-β estradiol
replacement in ApoE−/− ovariectomized mice showed that 17-β estradiol down-regulated
kidney ACE2 mRNA. This effect appeared to be mediated by ERα, since it was lost in the
ααee animals treated with 17-β estradiol. Because of the discrepancies of our data with previous
studies showing a positive effect of estrogen treatment on ACE2 regulation, it is not clear if
the findings in our study are related to the pathological background of the animals or to species
differences, since most previously reported studies were conducted in rats rather than mice.
Further assessment of the regulation of renal ACE2 by estrogen is warranted. There was no
significant interaction of estrogen with the ER for lung ACE2 mRNA. However, in ααee mice
17-β estradiol down-regulated lung ACE2 mRNA.
The AT2 receptor is highly expressed in the fetal rat kidney but its expression is markedly
reduced 3 months after birth (Kakuchi et al., 1995). In the adult rat kidney a low level of
expression of the AT2 receptor has been described (Ichiki & Inagami, 1995); however, in adult
mice kidney AT2 receptors are clearly expressed and associated with renal blood vessels,
glomeruli and tubular structures (Baiardi et al., 2005;Armando et al., 2002). Armando et al.
(Armando et al., 2002) found that female mice expressed much higher levels of AT2 receptors
and the expression of renal AT2 receptor in female mice was 17-β estradiol dependent. These
investigators describe a 60-fold increase in AT2 receptor binding in the inner medulla of
ovariectomized mice treated with 17-β estradiol, with additional but smaller increases in other
renal regions, including the capsule, glomeruli, and medullary rays. Our study showing a
marked increase in kidney AT2 receptor mRNA confirms the estrogen effect on AT2 receptor
in mice kidney. Because this increase in kidney AT2 receptor mRNA was lost in the ααee mice,
a primary role for the ERα receptor is likely. However, a role for ERβ cannot be eliminated,
since there was a trend for estrogen to increase the AT2 receptor mRNA in ααee mice, although
to a much lesser extent. Lefebvre et al (Lefebvre et al., 2006) showed that lung expresses the
AT2 receptor and that the expression of the AT2 receptor was unchanged with congestive heart
failure. To our knowledge, there have been no studies evaluating the role of estrogen on the
expression of AT2 receptors in the lung. Our study demonstrates that there is no significant
interaction of estradiol and ER in the regulation of the AT2 receptor mRNA in lung.
The studies were conducted in ApoEKO mice which is an excellent model of atherosclerosis.
Thus the studies evaluating estrogen’s regulation of RAS components in this model are relevant
to studies showing E2 protection in pathological conditions. However, it should be pointed out
that discrepancies between reports in the literature concerning E2 regulation of RAS
components may reflect the different models studied and thus may be a result of different
pathologies. In this study the findings may be influenced by the fact that they were conducted
in ApoEKO mice with and without an ERα receptor and, thus the results may be influenced
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by this background. Another consideration is that estrogen’s action in ovariectomized mice
may not necessarily reflect endogenous estrogen’s action in the intact female. In addition, it
remains possible that E2 loss via ovariectomy has no effect on RAS components when
compared to intact animals. Furthermore, a direct assessment of the role of ERβ needs to be
done in ERβKO mice to confirm the inferences made.
In conclusion, our study demonstrates that 17-β estradiol replacement exerts differential
regulation on components of the RAS. ERα was the primary receptor subtype responsible for
the regulation of kidney ACE2, AT1 receptor and AT2 receptor genes. The most dramatic effect
of 17-β estradiol was on the up-regulation of kidney AT2 receptor gene which may contribute
to the gender specific renal protective effects of estrogen. Finally, our data suggest that ERβ
may be primarily involved or contribute to the regulation of the ACE gene in the kidney and
the AT1 receptor gene in the lung.
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ACE, ACE2, AT1 receptor and AT2 receptor mRNAs (n=7-8/group) in the kidney of
ovariectomized ApoE knock-mice (ee) with (AA) (solid bar) and without (αα) (crosshatch bar)
the ERα receptor and either treated with placebo (white bar) or 17-β estradiol (grey bar). Values
expressed as mean ± SEM. Statistical analysis using the 2-way ANOVA revealed a significant
interaction of estrogen (p < 0.05) with ER for ACE, ACE2, AT1 receptor and AT2 receptor
mRNA. Fisher LSD multiple comparisons are indicated by * p < 0.05 vs placebo; ** p < 0.01
vs placebo; ***p < 0.001 vs placebo.
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ACE, ACE2, AT1 receptor and AT2 receptor mRNAs (n=7-8/group) in the lung of
ovariectomized apoE knock-out mice (ee) with (AA) and without (αα) the ERα receptor and
either treated with placebo (white bar) or 17-β estradiol (grey bar). Values are expressed as
mean ± SEM. Statistical analysis using the 2-way ANOVA revealed a significant interaction
of estrogen (p < 0.05) with ER for AT1 receptor mRNA, whereas there was only an effect of
17-β estradiol that was localized to ααee for ACE and ACE2 mRNA. * p<0.05 vs placebo.
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